Trial · NCT02867813
Results by group46
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 46
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | 2144 | Participants | ||
| Number of Participants Who Experienced an Adverse Event | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | 2084 | Participants | ||
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 12 | -55.93 | Standard Deviation 33.73 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 12 | -58.43 | Standard Deviation 30.64 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 24 | -56.69 | Standard Deviation 33.58 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 24 | -58.38 | Standard Deviation 31.52 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 48 | -58.52 | Standard Deviation 33.66 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 48 | -59.05 | Standard Deviation 33.06 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 72 | -56.35 | Standard Deviation 33.73 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 72 | -56.90 | Standard Deviation 33.14 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 96 | -55.70 | Standard Deviation 33.72 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 96 | -56.62 | Standard Deviation 33.36 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 120 | -53.37 | Standard Deviation 36.77 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 120 | -54.89 | Standard Deviation 35.99 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 144 | -56.96 | Standard Deviation 32.82 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 144 | -57.38 | Standard Deviation 32.34 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 168 | -56.49 | Standard Deviation 37.04 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 168 | -58.22 | Standard Deviation 34.60 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 192 | -57.42 | Standard Deviation 35.43 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Week 192 | -58.81 | Standard Deviation 33.27 | Percent Change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02867813/results